"Nestlé is shelling out an estimated $2.6 billion to buy a biopharmaceutical company best known for its peanut-allergy treatment"

"Aimmune Therapeutics' Palforzia is the first and only Food and Drug Administration-approved 'treatment to help reduce the frequency and severity of allergic reaction to peanuts, including anaphylaxis, in children aged 4 through 17.'"